BioDMARDs reduce polyimmunity in RA Danish Registry based cohort study 5 yrs follow up 25000+ pts Polyimmunity in csDMARDs treated group 2.2% vs. 1.7% in bioDMARDs group HR 0.74 Most frequent autoimmune thyroid disease POS0161 #EULAR2025 @RheumNow https://t.co/9T0mhoUuqs

In D2T-PsA (10%), 57% had persistent inflammation (PIPsA), 43% non-inflammatory (NIPsA). Ultrasound distinguished phenotypes: median US activity score 3.22 vs 0.88.,swollen joints 2.5 vs 0, tender points higher in NIPsA. Abstract OP0176 @RheumNow #EULAR2025 https://t.co/k7m8gAzbAZ

Nordic registries (n=13,872): D2T-PsA varied 37% (≥2 b/tsDMARDs failed) to 0.6% (strictest). Female predominance increased with therapy failures (≥4 failures: 67% female). Median time to failure: 5–7 years. Abstract OP0177 @RheumNow #EULAR2025 https://t.co/lchPnTCEx7

There is still hope for vagal nerve stimulation in RA! RCT RESET-RA 240+pts multibioIR Implantable cervical device Meets Primary endpoint ACR 20 wk12 Subgroup 1 prior bioDMARD ACR 20 wk12 46% vs 19% sham EULAR Good response 61% vs 42% sham Wk 12 SAE rate 1.7% #OP0190 #EULAR2025 https://t.co/DCON01XXgd

2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in remission at wk104. Low relapse rate, no loss of asthma control or decline of lung function. No new safety signals. @RheumNow #EULAR2025 #OP0166 https://t.co/kXh2q2ilJF

Difficult-to-treat & early PsA at #EULAR2025 GRAPPA definitions: D2T-PsA (≥3 therapies incl ≥2 b/tsDMARDs with persistent inflammation); C2M-PsA (broader: comorbidities, pain, intolerance). 95% GRAPPA consensus. Abstact OP0175 @RheumNow #EULAR2025 https://t.co/eqKmMPh80x

Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk of progression to RA. Total tenosynovitis Volume = incr. RA risk #EULAR2025 POS0472 https://t.co/eT0wbhp1uN

▶️Erosive hand OA 🔺Gull-wing erosion @ DIPJs ✅ 🔺Saw-tooth erosions @ PIPJs ✅ #OA #Osteoarthritis #EULAR2025 https://t.co/5Hh4Ki9P8V

Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down. If we don’t get in early with a right diagnosis (and maybe early steroid-sparing) then PMR patients deteriorate. We shouldn’t let PMR be an end stage disease #EULAR2025 POS0136 @RheumNow https://t.co/pqwveamhJP

In SLEek LTE, ABBV-599 HD (BTKi+JAKi) & UPA 30mg sustained or improved disease control through 104wks: SRI-4 ≥82%, ↓flares, near steroid-free, no new safety signals. PBO-switchers improved too. Targeted oral combos look promising. @RheumNow #EULAR2025 #OP0198 https://t.co/IHXC2iD0h6

Data from Dutch registry SpA-Net explored prevalence using new definitions for D2M axSpA. -Smoking and psoriasis were characteristics associated with D2M disease. -In the three variations explored, the lowest prevalence was observed in the variation based purely on objective https://t.co/h3f4ORQl0F

Sex differences in biologic response in PsA. DISCOVER-2 post hoc analysis showed: •Radiographic progression at Week ♂️: 2.22 units ♀️: 1.10 units •Early ACR-like response (cDAPSA LDA at 8wks) linked to less damage in men (0.39 vs 2.24) Women less likely to progress https://t.co/NhBkXbuLjO